Decoding Multiple Sclerosis Genetics: From Immune Risk to Disease Progression
The article by Bourguiba-Hachemi and colleagues presents multiple sclerosis (MS) as a complex neuroinflammatory disease shaped by the interaction of genetic susceptibility, environmental exposure, immune dysregulation, and neurodegenerative processes. The authors emphasize that MS genetics has moved far beyond the search for a single causal gene. Instead, the disease is now understood as highly polygenic, with more than 200 susceptibility-associated genomic regions contributing small but meaningful effects. This framework explains why MS risk differs across individuals, families, and populations, while also clarifying why genetic information alone cannot predict disease onset or clinical course with high precision. The review therefore positions MS as a model disease for modern post-GWAS biology, where genetic discoveries must be interpreted through immune pathways, ancestry, environmental factors, and longitudinal disease mechanisms.
The Central Role of the MHC and HLA Region
A major focus of the article is the major histocompatibility complex (MHC), located on chromosome 6p21, which remains the strongest genetic region associated with MS. Within this region, the HLA-DRB115:01 allele is described as the most robust and reproducible susceptibility factor, particularly in populations of European ancestry, where it confers an approximately two- to three-fold increase in risk. However, the authors argue that MS risk in the MHC should not be reduced to a single allele. Instead, susceptibility is better understood through conserved extended haplotypes, especially the HLA-DR15 haplotype involving HLA-DRB115:01, HLA-DQA101:02, and HLA-DQB106:02. Protective alleles, such as HLA-A*02:01, and complex interactions among HLA class I and class II alleles further demonstrate that antigen presentation and immune regulation operate within a broader haplotypic architecture.
GWAS and the Expansion of Non-HLA Susceptibility Loci
The article highlights genome-wide association studies as a decisive turning point in MS research. Early GWAS work identified non-HLA loci such as IL7R and IL2RA, demonstrating that cytokine signaling and lymphocyte regulation contribute to MS outside the classical HLA region. Larger collaborative studies, particularly those led by the International Multiple Sclerosis Genetics Consortium, expanded this landscape to more than 200 autosomal non-MHC susceptibility variants. Although most of these variants have modest individual effects, they converge biologically on immune pathways involving T-cell activation, B-cell function, cytokine signaling, antigen presentation, immune synapse formation, and costimulatory regulation. The article therefore reinforces the concept that MS susceptibility arises from altered thresholds of immune activation rather than from disruption of a single immune pathway.
Multi-Omics and Functional Interpretation of Risk Variants
A central scientific message of the review is that genetic association alone is insufficient to explain disease mechanisms. Most MS-associated variants are located in non-coding regions, suggesting that they influence disease primarily through gene regulation rather than direct changes in protein sequence. The authors describe how expression quantitative trait loci, chromatin accessibility data, epigenomic annotations, and single-cell approaches are increasingly used to connect risk variants to target genes and relevant cell types. These analyses implicate peripheral immune cells and microglia, while providing weaker support for direct neuronal or astrocytic enrichment in susceptibility. This shift from variant discovery to functional interpretation is crucial, because it allows researchers to transform statistical associations into mechanistic hypotheses about immune regulation, neuroinflammation, and CNS-resident immune activity.
From Susceptibility to Disease Progression
The article makes an important distinction between genetic factors that influence susceptibility and those that may affect disease severity or progression. Susceptibility variants are largely related to immune dysregulation, whereas progression-associated variants appear more connected to CNS resilience, neurodegeneration, membrane repair, and glial or neuronal survival. One highlighted example is rs10191329, located near DYSF and ZNF638, which has been associated with faster disability accumulation, increased CNS tissue injury, and elevated neurofilament light chain levels. DYSF is particularly relevant because it is involved in calcium-mediated membrane repair and is expressed in oligodendrocytes and neurons. This distinction supports a more nuanced model of MS: inflammatory genetic risk may initiate or facilitate disease, while separate mechanisms may influence long-term neurodegeneration and disability.
Rare Variants, Familial MS, and Ancestry-Dependent Risk
The review also examines rare variants and familial aggregation, concluding that they provide valuable biological clues but do not generally support a Mendelian model of MS inheritance. Familial MS is better interpreted as an enriched polygenic state involving common risk alleles, rare modifiers, shared environments, and early-life exposures. Whole-exome and whole-genome sequencing studies have identified candidate genes and pathways, including immune signaling, cytotoxicity, inflammasome biology, vitamin D metabolism, and CNS homeostasis, but replication remains difficult because of small sample sizes and incomplete penetrance. The authors also stress that MS genetics has been biased toward European ancestry populations. Risk allele frequencies and effect sizes differ across ancestries, and environmental factors such as sunlight exposure, vitamin D status, Epstein-Barr virus infection, smoking, geography, and socioeconomic context strongly confound ancestry-related interpretations.
Clinical Utility and Future Directions
Despite major scientific progress, the article concludes that the clinical utility of MS genetics remains limited and indirect. Current genetic findings can explain disease biology, clarify population-level risk, identify mechanistic pathways, and support development of improved disease models, but they cannot yet reliably predict individual disease onset, prognosis, disability progression, or treatment response. Genetic testing is therefore not currently a standard tool for routine MS diagnosis or therapeutic selection. The future of the field will depend on integrative, longitudinal models that combine genetic data with MRI, neurofilament light chain, clinical phenotypes, environmental exposure histories, epigenomics, transcriptomics, and ancestry-aware polygenic risk scores. In this framework, genetics will be most valuable not as a deterministic predictor, but as one component of a multimodal strategy for understanding MS heterogeneity and guiding more precise therapeutic research.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Bourguiba-Hachemi, S., Paris, J., Gourraud, P. A., & Vince, N. (2026). The genetic architecture of multiple sclerosis in 2026: From susceptibility to disease progression. Revue Neurologique.
